Anna H. Turaj

Southampton, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.

CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 29, 2025

Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate.

Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate.

Journal: PloS one

Published: January 20, 2023

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.

Journal: Nature cancer

Published: December 02, 2021

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.

Journal: Communications biology

Published: October 07, 2021

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression.

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression.

Journal: Blood advances

Published: May 04, 2020

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.

Journal: Scientific reports

Published: August 04, 2017

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.

Journal: Cancer cell

Published: April 11, 2017

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: March 02, 2017

TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter.

TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter.

Journal: Cancer research

Published: February 08, 2017

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.

Journal: Leukemia

Published: August 19, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026